Multi-Faceted Role of Luteolin in Cancer Metastasis: EMT, Angiogenesis, ECM Degradation and Apoptosis

Int J Mol Sci. 2023 May 16;24(10):8824. doi: 10.3390/ijms24108824.

Abstract

Luteolin (3',4',5,7-tetrahydroxyflavone), a member of the flavonoid family derived from plants and fruits, shows a wide range of biomedical applications. In fact, due to its anti-inflammatory, antioxidant and immunomodulatory activities, Asian medicine has been using luteolin for centuries to treat several human diseases, including arthritis, rheumatism, hypertension, neurodegenerative disorders and various infections. Of note, luteolin displays many anti-cancer/anti-metastatic properties. Thus, the purpose of this review consists in highlighting the relevant mechanisms by which luteolin inhibits tumor progression in metastasis, i.e., affecting epithelial-mesenchymal transition (EMT), repressing angiogenesis and lysis of extracellular matrix (ECM), as well as inducing apoptosis.

Keywords: flavonoids; metastasis prevention; phytochemicals; signaling pathways.

Publication types

  • Review

MeSH terms

  • Apoptosis
  • Cell Line, Tumor
  • Epithelial-Mesenchymal Transition
  • Flavonoids / pharmacology
  • Humans
  • Luteolin* / pharmacology
  • Luteolin* / therapeutic use
  • Neoplasms* / metabolism

Substances

  • Luteolin
  • Flavonoids

Grants and funding

This research received no external funding.